Skip to main content
Troisième phase d’évaluation clinique de l’application Antibiogo à Amman, Jordanie

Antibiogo: A revolutionary application to tackle antibiotic resistance

War in Gaza:: find out how we're responding
Learn more
  • MSF to launch approved application to tackle antibiotic resistance in low- and middle-income countries (LMIC).
  • The new application developed by MSF will allow doctors in LMIC to address antibiotic resistance in an effective, efficient and affordable way. 
  • The application could be key in slowing antibiotic resistance, which is recognised as a major public health threat. 

Paris – Recently CE-certified, the Antibiogo application will be deployed as of this summer in several Médecins Sans Frontières (MSF) laboratories. This innovative diagnostic tool, developed and tested by the MSF Foundation to meet the needs of low- and middle-income countries (LMIC) will eventually be available in the form of a free, offline and downloadable application, and offers considerable hope for slowing down antibiotic resistance, a major public health threat.

This diagnostic tool enables non-expert laboratory technicians to measure and interpret antibiograms, the test that determines the sensitivity of bacteria to different antibiotics. This test, which is essential to help doctors prescribe the most effective antibiotics to their patients, is usually interpreted by microbiologists who are not available in LMIC.

Antimicrobial resistance (AMR), recognised by the WHO as a major public health threat, caused 1.27 million deaths in 2019. It could become the leading cause of mortality with 10 million deaths per year globally from 2050 onwards if nothing is done.

Troisième phase d’évaluation clinique de l’application Antibiogo à Koutiala, Mali
A laboratory technician in Koutiala, Mali, prepares the inoculations of the positive readings. Mali, October 2021.   
Ismael Diallo

“Thanks to Antibiogo, any microbiology laboratory technician, anywhere in LMIC, will be able to read and interpret an antibiogram directly on their telephone and know the resistance profile of the bacteria responsible for patient infection, ” says Dr Nada Malou, head of the Antibiogo programme. 

“Properly used, it is a fantastic new diagnostic tool, which will help to ensure wider access to high-quality bacteriological tests even in the absence of microbiologists. This will make it possible not only to treat patients with the most appropriate antibiotics but also to reduce antibiotic resistance,” says Malou.
Furthermore, the vast majority of diagnostic tests are developed in high-income countries in line with market logic and then, once they have been made profitable, are made available to countries with limited resources without taking into account the specificity of their contexts. 

“Antibiogo is innovative in that it was created based on the need identified in countries with limited resources, was developed with users in these countries and with their data, and was tested in the people who are going to benefit from it. The development model of this medical device is the reverse of the one we usually observe, and meets real needs observed in LMIC,” says Malou.  


What is Antibiogo

The MSF Foundation / Loïc Adrien / Armelle Loiseau

In high-income countries, prescription of antibiotics is facilitated by the use of automated systems for reading and interpretation of antibiograms, and by the expertise of microbiologists. However, in LMIC, which do not have this expensive equipment or sufficient numbers of clinical microbiologists, identification of antibiotic resistance is much more complicated or often absent.
Antibiogo is based on image processing, artificial intelligence technology and an existing expert system. In practice, the application enables laboratory technicians to measure the inhibition diameters found on antibiograms and especially to interpret their results, without necessarily having expertise in microbiology 
In the field, the results show a very high level of concordance, ranging from 90-98 per cent depending on the bacteria, when they are compared with the interpretation made by qualified microbiologists.  
The Antibiogo mobile application developed by the MSF Foundation will be used first of all in MSF laboratories in Mali, the Central African Republic, Jordan and Yemen, and will subsequently be deployed more widely. In the long run, this tool is intended for healthcare professionals in all LMIC. After final certification is obtained in 2023, the application will be able to be downloaded by all microbiology laboratories in LMIC.

Up Next
Voices from the Field 15 May 2024